Report cover image

Biologics Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Product, By Service, By Source, By Workflow, By Therapeutic Area, By End Use, By Region, And Segment Forecasts, 2025 - 2033

Publisher Grand View Research
Published Oct 10, 2025
Length 120 Pages
SKU # GV20575048

Description

Biologics Contract Development And Manufacturing Organization Market Summary

The global biologics contract development and manufacturing organization market size was estimated at USD 19.22 billion in 2024 and is projected to reach USD 42.32 billion by 2033, growing at a CAGR of 9.21% from 2025 to 2033. The market is driven by the rising prevalence of chronic and rare diseases, an aging global population, and the growing demand for highly targeted therapies.

Besides, with the increasing need for biologics, the pharmaceutical and biopharmaceutical industry continues to show a surge in the number of companies opting for CDMO services. Furthermore, growing investments in biologics are expected to drive venture capital, strategic collaborations, mergers, and acquisitions, further contributing to market growth across the value chain. Most pharmaceutical & biopharmaceutical companies are increasingly partnering with CDMO service providers to expand capacity and access specialized technologies, while private equity and institutional investors are expanding their funds into platform companies with innovative models. In addition, most large pharmaceutical companies are focusing on acquisitions to strengthen their biologics pipelines, diversify therapeutic portfolios, and secure advanced manufacturing capabilities. Thus, these capital investments and strategic innovations are accelerating commercialization and reshaping the competitive landscape and are expected to drive the market in the coming years.

Moreover, with the growing focus on regulatory scenarios, the U.S. FDA, EMA, and other global authorities are refining approval pathways for biosimilars, cell therapies, and gene-based treatments, creating guidelines to encourage innovation while safeguarding patient safety. In addition, harmonized standards across regions support streamlining submissions and reducing delays, while post-market surveillance & evidence requirements remain stringent in the market. The evolving regulatory environment significantly enables faster approvals for novel therapies while raising the compliance burden on developers to meet rigorous chemistry, manufacturing, and control expectations. Such factors are expected to drive the market over the estimated time period.

Global Biologics Contract Development And Manufacturing Organization Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biologics contract development and manufacturing organization (CDMO) market report based on product, service, source, workflow, therapeutic area, end use, and region:
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Monoclonal antibodies (mAbs)
  • Recombinant proteins & enzymes
  • Vaccines
  • Cell & Gene Therapies
  • Nucleic acid Therapeutics
  • Others
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Contract Development
  • Cell Line Development
  • Process Development
  • Upstream
  • Downstream
  • Analytical Testing & Method Validation
  • Scale-Up & Tech Transfer
  • Contract Manufacturing
  • API Manufacturing
  • Finished Drug Products Manufacturing
  • Packaging and Labelling
  • Regulatory Affairs
  • Logistics & Storage
  • Others
  • Source Outlook (Revenue, USD Million, 2021 - 2033)
  • Mammalian
  • Microbial
  • Workflow Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical
  • Commercial
  • Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Autoimmune Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • Metabolic Diseases
  • Neurological Diseases
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical Companies
  • Biotechnology Companies
  • Academic and Research Institutions
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
  • Latin America
  • Brazil
  • Argentina
  • Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

120 Pages
Chapter 1. Research Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Value chain based analysis (Model 2)
1.7.3. Multivariate Analysis (Model 3)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Biopharmaceutical Contract Development and Manufacturing Organization Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising Demand for Biologics & Advanced Therapy
3.2.1.2. Rising Investment In R&D
3.2.1.3. Growing Biopharmaceutical Industry
3.2.2. Market Restraint Analysis
3.2.2.1. Compliance Issues While Outsourcing
3.2.2.2. Changing Scenarios In Developing Countries
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. Tariff Impact Analysis
3.6. Value Chain Analysis
3.6.1. Supply Trends
3.6.2. Demand Trends
3.7. Market Analysis Tools
3.7.1. Porter’s Five Force Analysis
3.7.2. PESTEL by SWOT Analysis
Chapter 4. Biopharmaceutical Contract Development and Manufacturing Organization Market: Product Estimates & Trend Analysis
4.1. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Product: Segment Dashboard
4.2. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Product: Movement Analysis
4.3. Biopharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Product, 2021 - 2033 (USD Million)
4.4. Monoclonal Antibodies (mAbs)
4.4.1. Monoclonal antibodies (mAbs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Recombinant Proteins & Enzymes
4.5.1. Recombinant Proteins & Enzymes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Vaccines
4.6.1. Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Cell & Gene Therapies
4.7.1. Cell & Gene Therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.8. Nucleic acid Therapeutics
4.8.1. Nucleic Acid Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.9. Others
4.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Biopharmaceutical Contract Development and Manufacturing Organization Market: Service Estimates & Trend Analysis
5.1. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Service: Segment Dashboard
5.2. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Service: Movement Analysis
5.3. Biopharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
5.4. Contract Development
5.4.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.2. Cell Line Development
5.4.2.1. Cell Line Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.3. Process Development & Optimization
5.4.3.1. Process Development & Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.3.2. Upstream
5.4.3.2.1. Upstream Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.3.3. Downstream
5.4.3.3.1. Downstream Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.4. Analytical Testing & Method Validation
5.4.4.1. Analytical Testing & Method Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.5. Scale-up & Tech Transfer
5.4.5.1. Scale-up & Tech Transfer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Contract Manufacturing
5.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5.2. API Manufacturing
5.5.2.1. API Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5.3. Finished drug products Manufacturing
5.5.3.1. Finished drug products Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Packaging and Labelling
5.6.1. Packaging and Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Regulatory Affairs
5.7.1. Regulatory Affairs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.8. Logistics & Storage
5.8.1. Logistics & Storage Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.9. Others
5.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Biopharmaceutical Contract Development and Manufacturing Organization Market: Source Estimates & Trend Analysis
6.1. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Source: Segment Dashboard
6.2. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Source: Movement Analysis
6.3. Biopharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Source, 2021 - 2033 (USD Million)
6.4. Mammalian
6.4.1. Mammalian Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Microbial
6.5.1. Microbial Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Biopharmaceutical Contract Development and Manufacturing Organization Market: Workflow Estimates & Trend Analysis
7.1. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Workflow: Segment Dashboard
7.2. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Workflow: Movement Analysis
7.3. Biopharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)
7.4. Clinical
7.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Commercial
7.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Biopharmaceutical Contract Development and Manufacturing Organization Market: Therapeutic Area Estimates & Trend Analysis
8.1. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Therapeutic Area: Segment Dashboard
8.2. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Therapeutic Area: Movement Analysis
8.3. Biopharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033 (USD Million)
8.4. Oncology
8.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Autoimmune Diseases
8.5.1. Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Infectious Diseases
8.6.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. Cardiovascular Diseases
8.7.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8. Metabolic Diseases
8.8.1. Metabolic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.9. Neurological Diseases
8.9.1. Neurological Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.10. Others
8.10.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Biopharmaceutical Contract Development and Manufacturing Organization (CDMO) Market: End Use Estimates & Trend Analysis
9.1. Biopharmaceutical Contract Development and Manufacturing Organization Market, By End Use: Segment Dashboard
9.2. Biopharmaceutical Contract Development and Manufacturing Organization Market, By End Use: Movement Analysis
9.3. Biopharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
9.4. Pharmaceutical Companies
9.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5. Biotechnology Companies
9.5.1. Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.6. Academic and Research Institutions
9.6.1. Academic and Research Institutions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.7. Others
9.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 10. Biologics Contract Development And Manufacturing Organization (CDMO) Market: Regional Estimates & Trend Analysis
10.1. Regional Market Dashboard
10.2. Regional Market Share Analysis, 2024 & 2033
10.3. North America
10.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.3.2. U.S
10.3.2.1. Key Country Dynamics
10.3.2.2. Competitive Scenario
10.3.2.3. Regulatory Framework
10.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.3.3. Canada
10.3.3.1. Key Country Dynamics
10.3.3.2. Competitive Scenario
10.3.3.3. Regulatory Framework
10.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.3.4. Mexico
10.3.4.1. Key Country Dynamics
10.3.4.2. Competitive Scenario
10.3.4.3. Regulatory Framework
10.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4. Europe
10.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4.2. UK
10.4.2.1. Key Country Dynamics
10.4.2.2. Competitive Scenario
10.4.2.3. Regulatory Framework
10.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4.3. Germany
10.4.3.1. Key Country Dynamics
10.4.3.2. Competitive Scenario
10.4.3.3. Regulatory Framework
10.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4.4. France
10.4.4.1. Key Country Dynamics
10.4.4.2. Competitive Scenario
10.4.4.3. Regulatory Framework
10.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4.5. Italy
10.4.5.1. Key Country Dynamics
10.4.5.2. Competitive Scenario
10.4.5.3. Regulatory Framework
10.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4.6. Spain
10.4.6.1. Key Country Dynamics
10.4.6.2. Competitive Scenario
10.4.6.3. Regulatory Framework
10.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4.7. Denmark
10.4.7.1. Key Country Dynamics
10.4.7.2. Competitive Scenario
10.4.7.3. Regulatory Framework
10.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4.8. Sweden
10.4.8.1. Key Country Dynamics
10.4.8.2. Competitive Scenario
10.4.8.3. Regulatory Framework
10.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4.9. Norway
10.4.9.1. Key Country Dynamics
10.4.9.2. Competitive Scenario
10.4.9.3. Regulatory Framework
10.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5. Asia Pacific
10.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.2. Japan
10.5.2.1. Key Country Dynamics
10.5.2.2. Competitive Scenario
10.5.2.3. Regulatory Framework
10.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.3. China
10.5.3.1. Key Country Dynamics
10.5.3.2. Competitive Scenario
10.5.3.3. Regulatory Framework
10.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.4. India
10.5.4.1. Key Country Dynamics
10.5.4.2. Competitive Scenario
10.5.4.3. Regulatory Framework
10.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.5. Australia
10.5.5.1. Key Country Dynamics
10.5.5.2. Competitive Scenario
10.5.5.3. Regulatory Framework
10.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.6. Thailand
10.5.6.1. Key Country Dynamics
10.5.6.2. Competitive Scenario
10.5.6.3. Regulatory Framework
10.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.7. South Korea
10.5.7.1. Key Country Dynamics
10.5.7.2. Competitive Scenario
10.5.7.3. Regulatory Framework
10.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.6. Latin America
10.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.6.2. Brazil
10.6.2.1. Key Country Dynamics
10.6.2.2. Competitive Scenario
10.6.2.3. Regulatory Framework
10.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.6.3. Argentina
10.6.3.1. Key Country Dynamics
10.6.3.2. Competitive Scenario
10.6.3.3. Regulatory Framework
10.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.7. Middle East and Africa
10.7.1. Middle East and Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.7.2. South Africa
10.7.2.1. Key Country Dynamics
10.7.2.2. Competitive Scenario
10.7.2.3. Regulatory Framework
10.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.7.3. UAE
10.7.3.1. Key Country Dynamics
10.7.3.2. Competitive Scenario
10.7.3.3. Regulatory Framework
10.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.7.4. Saudi Arabia
10.7.4.1. Key Country Dynamics
10.7.4.2. Competitive Scenario
10.7.4.3. Regulatory Framework
10.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.7.5. Kuwait
10.7.5.1. Key Country Dynamics
10.7.5.2. Competitive Scenario
10.7.5.3. Regulatory Framework
10.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.7.6. Qatar
10.7.6.1. Key Country Dynamics
10.7.6.2. Competitive Scenario
10.7.6.3. Regulatory Framework
10.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.7.7. Oman
10.7.7.1. Key Country Dynamics
10.7.7.2. Competitive Scenario
10.7.7.3. Regulatory Framework
10.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 11. Competitive Landscape
11.1. Key Participant Categorization
11.1.1. Market Leaders
11.1.2. Emerging Players
11.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
11.3. Company Profiles
11.3.1. Lonza Group
11.3.1.1. Company Overview
11.3.1.2. Financial Performance
11.3.1.3. Service Benchmarking
11.3.1.4. Strategic Initiatives
11.3.2. Catalent Pharma Solutions
11.3.2.1. Company Overview
11.3.2.2. Financial Performance
11.3.2.3. Service Benchmarking
11.3.2.4. Strategic Initiatives
11.3.3. Samsung Biologics
11.3.3.1. Company Overview
11.3.3.2. Financial Performance
11.3.3.3. Service Benchmarking
11.3.3.4. Strategic Initiatives
11.3.4. WuXi Biologics / WuXi AppTec
11.3.4.1. Company Overview
11.3.4.2. Financial Performance
11.3.4.3. Service Benchmarking
11.3.4.4. Strategic Initiatives
11.3.5. Thermo Fisher Scientific
11.3.5.1. Company Overview
11.3.5.2. Financial Performance
11.3.5.3. Service Benchmarking
11.3.5.4. Strategic Initiatives
11.3.6. Fujifilm Diosynth Biotechnologies
11.3.6.1. Company Overview
11.3.6.2. Financial Performance
11.3.6.3. Service Benchmarking
11.3.6.4. Strategic Initiatives
11.3.7. Boehringer Ingelheim (Biopharma CDMO)
11.3.7.1. Company Overview
11.3.7.2. Financial Performance
11.3.7.3. Service Benchmarking
11.3.7.4. Strategic Initiatives
11.3.8. Rentschler Biopharma SE
11.3.8.1. Company Overview
11.3.8.2. Financial Performance
11.3.8.3. Service Benchmarking
11.3.8.4. Strategic Initiatives
11.3.9. AGC Biologics
11.3.9.1. Company Overview
11.3.9.2. Financial Performance
11.3.9.3. Service Benchmarking
11.3.9.4. Strategic Initiatives
11.3.10. Charles River Laboratories
11.3.10.1. Company Overview
11.3.10.2. Financial Performance
11.3.10.3. Service Benchmarking
11.3.10.4. Strategic Initiatives
11.3.11. Siegfried Holding
11.3.11.1. Company Overview
11.3.11.2. Financial Performance
11.3.11.3. Service Benchmarking
11.3.11.4. Strategic Initiatives
11.3.12. Sandoz
11.3.12.1. Company Overview
11.3.12.2. Financial Performance
11.3.12.3. Service Benchmarking
11.3.12.4. Strategic Initiatives
11.3.13. GenScript Biologics
11.3.13.1. Company Overview
11.3.13.2. Financial Performance
11.3.13.3. Service Benchmarking
11.3.13.4. Strategic Initiatives
11.3.14. Vetter Pharma
11.3.14.1. Company Overview
11.3.14.2. Financial Performance
11.3.14.3. Service Benchmarking
11.3.14.4. Strategic Initiatives
11.3.15. IDT Biologika
11.3.15.1. Company Overview
11.3.15.2. Financial Performance
11.3.15.3. Service Benchmarking
11.3.15.4. Strategic Initiatives

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us